top of page



Where To Buy Lufenuron

In older times, flea control for pets was all about shampoos, sprays, foggers, flea collars and powders. The U.S. market had been long in search of a flea product that was safe, convenient, and effective and many companies were racing to bring out their new product first. Ciba Animal Health won this battle in 1995 with the approval of lufenuron for use in U.S. pets. The introduction of lufenuron marked what is called the "revolution" in flea control where products shifted towards monthly oral and topical products and away from the labor-intensive materials of the past. Lufenuron does not kills fleas but it is highly effective at ending flea reproduction. This means that it is best used in combination with other products. It is presently available as an over-the-counter oral medication or as an "every six month" injectable for cats.

where to buy lufenuron


By the time a flea has reached adulthood and is taking blood meals from a pet, it has made all the chitin it needs and is not directly affected by the lufenuron it is drinking in the pet's blood. The female flea, however, is largely drinking blood to support egg-laying (up to 40 eggs daily) and the larvae developing inside these eggs must make chitin in order to chip their way out of the egg. If the mother flea has passed along a healthy dose of lufenuron to her eggs, they will not be able to hatch.

Adult fleas feeding on a pet will be continually producing the black specks of digested blood called flea dirt. This material is highly nutritious for larvae developing in the environment but if this flea dirt is packed with lufenuron, the larvae will not be able to grow normal exoskeletons and they will die.

The injectable formula for cats was designed as an alternative to the relatively unpopular and now discontinued oral liquid. Like the oral product, injectable lufenuron is stored in body fat. One injection is effective for 6 months.

Fleas are not the only organisms to contain chitin. Apparently some fungi also are affected by lufenuron. An "anti-ringworm" dose, which is much higher than the flea preventive dose, has been published to aid in the treatment of dermatophytosis (more commonly known as "ringworm.") The efficacy of lufenuron for fungal diseases has not panned out, however, and this unapproved use of lufenuron should be considered as only an adjunct to more traditional therapies, if at all. Lufenuron should not be used as a sole therapy for ringworm. As for other fungi, lufenuron use seems cost prohibitive but may be of benefit as adjunctive therapy.

It is important to note that with the advent of popular top-spot and oral treatments for fleas, special attention should be paid to the development of resistance to these products. Experience with other insects tells us that resistance can develop in 12 to 15 generations. In order to preserve these new insecticides, it is important to consider what is called integrated pest management. What this means is that insecticides should be rotated or combined with insect development inhibitors such as lufenuron or insect growth regulators like methoprene or pyriproxifen (substances that interfere with the maturation of flea larvae). Adding a second product that breaks the flea life cycle in another stage is very helpful in preventing the development of resistance. Lufenuron may be used in combination with any of the popular effective topicals or oral products to achieve this end.

In order for lufenuron to work, fleas must bite the pet, potentially a problem for the flea allergic pet. For pets with flea bite allergy, lufenuron would best be combined with a product that actually kills fleas. There is at present no flea product that can kill fleas before they bite.

Preventer Plus Flavor Tabs (milbemycin oxime + lufenuron) are available in four tablet sizes in color-coded packages for oral administration to dogs and puppies according to their weight. Each tablet is formulated to provide a minimum of 0.23 mg/lb (0.5 mg/kg) body weight of milbemycin oxime and 4.55 mg/pound (10 mg/kg) body weight of lufenuron. Milbemycin oxime consists of the oxime derivatives of 5-didehydromilbemycins in the ratio of approximately 80% A4 and 20% A3 Milbemycin oxime is classified as a macrocyclic antihelminthic.

Preventer Plus Flavor Tabs are palatable and most dogs will consume the tablet when offered by the owner. As an alternative to direct dosing, the tablets can be hidden in food. Be certain the dog consumes the entire tablet. Administer Preventer Plus Flavor Tabs to dogs immediately after or in conjunction with a normal meal. Food is essential for adequate absorption of lufenuron. Watch the dog closely following administration to be sure the entire dose have been consumed

Preventer Plus Flavor Tabs must be administered monthly, preferably on the same date each month. Treatment may begin at any time of year. In geographic areas where mosquitoes and fleas are seasonal, the treatment schedule should begin one month prior to the expected onset and should continue until the end of mosquito and flea season. In areas with year-round infestations, treatment should continue through the entire year without interruption.

The palatable once-a-month prescription tablet that prevents heartworm disease and flea populations in dogs and puppies. SENTINEL (milbemycin oxime/lufenuron) Flavor Tabs also control flea populations and adult hookworms, and remove and control adult roundworm and whipworm infection in dogs and puppies.

Lufenuron is a benozylphenylurea derivative with the following chemical composition: N-[2,5-dichloro-4-(1,1,2,3,3,3, - hexafluoropropoxy)-phenylaminocarbonyl]-2,6- difluorobenzamide (C17H8Cl2F8N2O3, MW 511.15). Benzozylphenylurea compounds, including lufenuron, are classified as insect development inhibitors (IDIs).

When treatment was initiated during the flea season, lufenuron tablets were effective in controlling flea infestations on dogs that completed the study. The mean flea count per lufenuron-treated dog was approximately 74 prior to treatment but had decreased to 4 after six monthly doses of lufenuron. A topical adulticide was used in the first eight weeks of the study to kill the pre-existing adult fleas.

Two studies in heartworm-infected dogs were conducted which demonstrated mild, transient hypersensitivity reactions in treated dogs with high microfilaremia counts (see Precautions for reactions observed). Safety studies in pregnant dogs demonstrated that high doses (1.5 mg/kg = 3X) of milbemycin oxime given in an exaggerated dosing regimen (daily from mating through weaning), resulted in measurable concentrations of the drug in milk. Puppies nursing these females which received exaggerated dosing regimens demonstrated milbemycin-related effects. These effects were directly attributable to the exaggerated experimental dosing regime. The product is normally intended for once-a-month administration only. Subsequent studies included using 3X daily from mating to one week before weaning and demonstrated no effects on the pregnant females or their litters. A second study where pregnant females were dosed once at 3X the monthly use rate either before, on the day of or shortly after whelping resulted in no effects on the puppies.

Four reproductive safety studies were conducted in breeding dogs with lufenuron tablets: two laboratory and two well-controlled clinical studies. In one of the laboratory studies, where lufenuron was administered to beagle dogs at doses equivalent to 90X (3X daily) the monthly recommended dose of 10 mg/kg, the ratio of gravid females to females mated was 8/8 or 100% in the control group and 6/9 or 67% in the lufenuron-treated group. The mean number of pups per litter was two animals higher in the treated versus control groups and the mean birth weights of pups from treated bitches in this study was lower than control groups.

These pups grew at a similar rate to control pups. There was a higher incidence of four clinical signs in the lufenuron-treated versus control group: nasal discharge, pulmonary congestion, diarrhea/dehydration and sluggishness. The incidence of these signs was transient and decreasing by the end of lactation. Results from three additional reproductive safety studies, one laboratory and two clinical field studies evaluating eleven breeds of dogs, did not demonstrated any adverse finding for the reproductive parameters measured including fertility, pup birth weights and pup clinical signs after administration of lufenuron up to 5X the recommended monthly use rate.

Data from analysis of milk from lactating animals treated with lufenuron tablets of 2X and 6X the recommended monthly use rate demonstrates that lufenuron concentrates in the milk of these dogs. The average milk: blood concentration ratio was approximately 60 (i.e., 60X higher drug concentrations in the milk compared to drug levels in the blood of treated bitches). Nursing puppies averaged 8-9 times higher blood concentrations of lufenuron compared to their dams.

This insert describes the concurrent use of SENTINEL (milbemycin oxime/lufenuron) Flavor Tabs and CAPSTAR (nitenpyram) Tablets for the management of fleas on dogs and puppies. Please read the insert contained in each package for complete information of the individual products prior to dispensing or dosing. The effects of Sentinel Flavor Tabs on heartworm disease and internal parasites are not described in this supplement.

Each tablet is formulated to provide a minimum of 0.23 mg/lb (0.5 mg/kg) body weight of milbemycin oxime and 4.55 mg/pound (10 mg/kg) body weight of lufenuron. Milbemycin oxime consists of the oxime derivatives of 5-didehydromilbemycins in the ratio of approximately 80% A4 and 20% A3. Milbemycin oxime is classified as a macrocyclic anthelmintic. Lufenuron is a benozylphenylurea derivative and is classified as an insect development inhibitor.

Administer Preventer Plus Flavor Tabs to dogs immediately after or in conjunction with a normal meal. Food is essential for adequate absorption of lufenuron. Watch the dog closely following administration to be sure the entire dose has been consumed. 041b061a72


グループページ: Groups_SingleGroup
bottom of page